Oppenheimer & Co. Inc. Sells 17,689 Shares of GlaxoSmithKline plc (GSK)

Oppenheimer & Co. Inc. trimmed its holdings in GlaxoSmithKline plc (NYSE:GSK) by 19.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 74,802 shares of the pharmaceutical company’s stock after selling 17,689 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in GlaxoSmithKline were worth $2,652,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of GSK. Field & Main Bank purchased a new stake in GlaxoSmithKline in the fourth quarter valued at $132,000. Wealthcare Advisory Partners LLC boosted its holdings in GlaxoSmithKline by 1,982.8% in the third quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after purchasing an additional 3,351 shares during the last quarter. Advisory Services Network LLC boosted its holdings in GlaxoSmithKline by 24.2% in the second quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after purchasing an additional 788 shares during the last quarter. Waldron LP purchased a new stake in GlaxoSmithKline in the third quarter valued at $203,000. Finally, Belpointe Asset Management LLC purchased a new stake in GlaxoSmithKline in the third quarter valued at $204,000. 9.52% of the stock is currently owned by institutional investors.

Shares of GlaxoSmithKline plc (NYSE:GSK) opened at $36.46 on Wednesday. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. GlaxoSmithKline plc has a 12 month low of $34.52 and a 12 month high of $44.53. The stock has a market cap of $89,916.88, a PE ratio of 12.55, a PEG ratio of 2.30 and a beta of 0.98.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The business had revenue of $10.14 billion for the quarter, compared to analyst estimates of $9.89 billion. research analysts predict that GlaxoSmithKline plc will post 2.82 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be paid a dividend of $0.633 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 annualized dividend and a dividend yield of 6.94%. The ex-dividend date of this dividend is Thursday, February 22nd. GlaxoSmithKline’s dividend payout ratio is presently 258.23%.

GSK has been the topic of several recent research reports. TheStreet raised shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Argus lowered their price target on shares of GlaxoSmithKline to $40.00 and set a “buy” rating on the stock in a report on Thursday, November 30th. UBS Group raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and upped their price target for the company from $35.04 to $35.85 in a report on Monday, November 27th. Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Wednesday, October 18th. Finally, ValuEngine lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Sunday, December 31st. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and six have given a buy rating to the company’s stock. GlaxoSmithKline currently has an average rating of “Hold” and an average price target of $38.57.

ILLEGAL ACTIVITY WARNING: “Oppenheimer & Co. Inc. Sells 17,689 Shares of GlaxoSmithKline plc (GSK)” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/14/oppenheimer-co-inc-sells-17689-shares-of-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply